News & Analysis as of

Intellectual Property International Trade

Read Intellectual Property Law updates, alerts, news, and legal analysis from leading lawyers and law firms:

Global Intellectual Property Indicator in 2017 Published by WIPO

World Intellectual Property Organization (WIPO) published its annual report, Global Intellectual Property Indicator 2017, on January 8, 2018. The report is 226 pages long and contains mostly statistics and colorful graphs....more

Rising Tensions As Trump Administration Prepares To Announce Results Of Section 301 Trade Investigation Into China’s Alleged...

As we previously reported, on August 14, 2017, President Trump signed an executive memo asking U.S. Trade Representative Robert Lighthizer to determine whether to launch an investigation into China’s alleged theft of...more

The Supreme Court to Consider Patent Infringement Damages Accrued Abroad

by Snell & Wilmer on

The Supreme Court has granted certiorari to consider whether damages for infringement of a U.S. patent include lost profits resulting from activities outside the U.S....more

EU Trademarks and Brexit: Are You Ready?

There continues to be a high level of uncertainty regarding the impact of Brexit on the rights of EU trademark owners. For the last 21 years, the EU Trademark Registration (EUTM), formerly known as the Community Trademark or...more

Broad Institute CRISPR-Cas9 patent revoked in Europe

by Allen & Overy LLP on

17 January 2018 – the Opposition Division (OD) of the European Patent Office (EPO) has today revoked one of the Broad Institute’s foundational CRISPR-Cas9 patents in Europe (EP2771468), upholding the preliminary opinion,...more

Global Patent Prosecution Newsletter - January 2018

Double Patenting and Divisional Applications - Many countries allow an applicant to protect multiple inventions disclosed in a single application in one or more continuing applications. In most countries divisional...more

Trade & Manufacturing - News of Note - January 2018

by King & Spalding on

The United States Trade Representative (USTR) issued a request for comments and notice of public hearing regarding the 2018 Special 301 Review. The review is a Congressionally-mandated annual review of the global state of...more

Heavy jail sentence handed down on illegal set-top boxes sellers in Hong Kong

by Hogan Lovells on

On 28 December 2017, the District Court of Hong Kong handed down sentences varying from 21 to 27 months’ imprisonment against 3 individuals who took part in a scheme that enabled users of the “Maige Set Top Box” (the “Maige...more

Inducement After Importation Actionable Under Section 337

by Jones Day on

Complainants often must rely on indirect infringement to prove a violation of Section 337. Indirect infringement may be in the form of induced or contributory infringement. In a recent opinion, the Commission clarified issues...more

CJEU Confirms: Supplemental Protection Certificate Application Requires Issued Marketing Authorization

by K&L Gates LLP on

A recent decision of the CJEU in Europe raises concerns for pharmaceutical companies who wish to supplement the protection of their products with SPCs. With its decision C 567/16 the court follows a strict approach and...more

Update on US Investigation of China’s IP Practices

Further to our alert published on November 13, 2017 regarding whether acts, policies, and practices (“APPs”) of China related to transfer of technology, intellectual property, and innovation are actionable under Section...more

International Trademark Law: Thoughts on Japan’s Post-Registration Opposition Proceedings

by Revision Legal on

Most nations with fully-developed trademark legal frameworks allow for opposition proceedings with regard to newly filed applications for trademarks. Most jurisdictions, like the United States, provide that opposition...more

Hetero and Glenmark Launch Adalimumab Biosimilars in India

by Goodwin on

Hetero announced this week the launch in India of its adalimumab biosimilar, marketed under the brand name Mabura. Mabura is a biosimilar of Abbvie’s Humira and is indicated for the treatment of rheumatoid arthritis and other...more

2018: Predictions From Socially Aware’s Editors and Contributors

Happy 2018 to our readers! It has become a Socially Aware tradition to start the New Year with some predictions from our editors and contributors. With smart contracts on the horizon, the Internet of Things and...more

DSM Watch: Leaked JRC Study calls into question neighbouring right for press publishers

by Hogan Lovells on

The evolution of a new neighbouring right for press publishers is currently the subject of wide and heated debate. The European Commission proposed such a right in Article 11 of its proposal for a new directive on copyright...more

Patentability of Diagnostic Methods in Europe

Like the USPTO, the European Patent Office (EPO) considers that the discovery of a natural phenomenon is not patent eligible. However, unlike the USPTO, the EPO takes the view that a patentable invention can derive from a...more

What’s up with WHOIS? The GDPR May Limit or Prevent Access to Domain Name Registration Information

by Dorsey & Whitney LLP on

Domain name registrars and registries might soon be changing their mantra from, “I think ICANN,” to, “Maybe ICANN’T,” when it comes to providing publicly available WHOIS information for domain name registrants. New potential...more

Year in Review: The Most Popular Blog Posts of 2017

As 2018 begins and IP strategies are being developed for the new year, it is a good time to reflect on what IP issues were prominent in 2017. According to the many readers of Global IP Matters, hot topics included navigating...more

Claim Drafting Strategy for Filing in the US and Europe

by Workman Nydegger on

Although obtaining a patent in Europe is similar to the process of obtaining a patent in the US, there are some important distinctions that should be considered when drafting a patent application that will be filed in both...more

Mylan and Biocon Gain Approval for Trastuzumab Biosimilar in Brazil

by Goodwin on

On December 29, Mylan and Biocon announced that their trastuzumab biosimilar, Zedora, was approved by Brazil’s National Sanitary Surveillance Agency. Zedora, a biosimilar of Genentech and Roche’s Herceptin, is indicated for...more

Trademark Practice Update: Scandalous? Immoral? It's all Good

On December 15, 2017, the U.S. Court of Appeals for the Federal Circuit held that the Lanham Act’s prohibitions on registering scandalous and immoral marks discriminated based on content, and violated the First Amendment (In...more

New Year's Resolutions For The U.S. Patent System

by Foley & Lardner LLP on

It’s that time of year when we make resolutions to improve our health, our relationships, our careers, or other areas of our lives. I’m not starting a new diet today (although if I were, the invention described in this patent...more

Sites get ICEd in transatlantic assault on cyber crooks

by Hogan Lovells on

As part of a sustained and coordinated effort, law enforcement agencies on both sides of the Atlantic have rounded off their on-going fight against cybercrime known as “Operation In Our Sites” with the traditional annual...more

Top 5 Design Offices Meet in Alicante to Discuss Protection of Emerging Designs

On December 4 and 5, 2017, the members of the Industrial Design 5 (ID5) met at the EUIPO offices in Alicante, Spain for the 3rd ID5 Annual Meeting. The ID5 is an Industrial design framework comprised of the European Union...more

Worldwide Bolar-type Provisions*

Please see full chart for Bolar Excemption rules in foreign countries regarding Clinical Trials, New Drugs, Biosimilars and Foreign Jurisdiction issues. ...more

2,783 Results
|
View per page
Page: of 112
Cybersecurity

Follow Intellectual Property Updates on:

"My best business intelligence,
in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.